Financing channel feed – Endpoints News

Financing channel feed

The pandemic IPOs keep rolling, as Generation, Avidity, Vaxcyte each claim 200M+

5 years ago

A storied Chinese pharma partner of Bristol Myers, Amgen — and avid biotech supporter — plots HK IPO

5 years ago

Juno, WuXi JV in China score $100M in fresh funding as it sets stage for first CAR-T approval

5 years ago

'Tremendous' animal data inspire GV, ARCH's $63M booster for Sekar Kathiresan's drive to relegate coronary heart disease to history

5 years ago

IPO bound? Five years in, Art Krieg and the Checkmate crew collect $85M to back up their 1-drug pipeline

5 years ago

Going where PROTACs can't, Versant unveils $50M bet on Carolyn Bertozzi's LYTAC tech — with a rising star at the helm

5 years ago

ARCH-backed Autobahn launches with $76M to rebuild myelin and reverse MS

5 years ago

Capitalizing Pablo II: The updated IPO for Royalty Pharma includes a $16.6B market cap and a chart-topping $2.2B raise. Can they beat it?

5 years ago

Biopharma IPO boom yields buoyant biotech public debuts

5 years ago

Add ear gene therapy company Akouos to the ever-growing list of IPOs amid Covid-19

5 years ago

Legend fetches $424 million, emerges as biggest winner yet in pandemic IPO boom as shares soar

6 years ago

RA Capital, Hillhouse join $310M rush to back Everest's climb to commercial heights in China

6 years ago

Portion of Neil Woodford’s remaining investments, including Nanopore, sold off for $284 million

6 years ago

Atlas raises new $400M fund amid spree of VC raises. Here’s what they’ll spend it on

6 years ago

Can a small biotech successfully tackle an Everest climb like Alzheimer’s? Athira has $85M and some influential backers ready to give it a shot

6 years ago

Bullish biotech market propels Pliant to $144M IPO — as Novartis provides a $10M boost

6 years ago

As NLRP3 players head for first clinical face-off, Novo, Sanofi fuel trans-Atlantic contender with $55M

6 years ago

Hillhouse recasts spotlight on China's biotech scene with $160M round for Shanghai-based antibody maker

6 years ago

Pfizer’s Doug Giordano has $500M — and some advice — to offer a certain breed of 'breakthrough' biotech

6 years ago

IPOs abound in the time of coronavirus, as Forma Therapeutics pencils in $150M Nasdaq debut

6 years ago

Versant-backed, Bristol Myers-stamped Repare Therapeutics guns for $100M IPO

6 years ago

The big money: Poised to make drug R&D history, a China biotech unveils unicorn racing ambitions in a bid to raise $350M-plus on Nasdaq

6 years ago

For a post-Soliris world, Atlas-backed Q32 Bio outlines $46M next-gen complement play

6 years ago

AbCellera raises $105M in first major venture round as Covid-19 antibody nears clinic

6 years ago

First page Previous page 98 99 100101102 103 104 Next page Last page